Investors & media




INVESTOR INFORMATION: KEY FACTS




Stock Market NYSE Euronext Paris - Eurolist (compartment B)
Reuters /Bloomberg TRNG.PA / TNG.FP
ISIN Code FR0005175080
Total number of shares outstanding 31 782 940
First Quote on Nouveau Marché & Nasdaq* 26 March 1998
Local Sector Index Next Biotech / CAC Mid 100
Financial Year Ends December 31

 

 


Funding History

 

Date Operation Capital Raised
June   2010
Capital Increase
€152.0 million
June   2007
Capital Increase
€100.1 million
July    2006
Capital Increase/Warrants Exercised
€14.3 million
June   2005 Capital Increase on Euronext Paris
€34.9 million
May    2001
Follow-on Nouveau Marché & Nasdaq
€63.1 million
March 1998
IPO Nouveau Marché & Nasdaq* US$100 million

*De-listed from Nasdaq 23 September, 2005



Shareholding Structure

 

55 % Institut Merieux
27 % Institutional Shareholders
16 % Retail
2 % Others

 



Key Financial Highlights (€ Million)

 

Year Cash Burn (net) R&D expenditure

Cash & cash equivalents

2012 46.6 48.7 92.9
2011 39.6(3) 53.0 139.5
2010 28.8(2) 42.5 180.3
2009 22.0 33.0 64.7
2008 24.6
32.3
86.7
2007
5.5(1) 28.8
111.3
2006
20.6
24.2
20.3
2005 20.7 20.9 26.5

(3) Excluding investment in Jennerex Inc.

(2) Excluding capital increase and investment in Jennerex Inc.

(1) Includes €23m received from Roche